BioNTech SE Sponsored ADR

BNTX Healthcare Biotechnology

BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue fell 58.5%, EPS fell 107.1%, free cash flow fell 342.0% and total debt rose 20.1%, each against the same quarter a year earlier.

87.57 2.63 −2.92%
Market cap
$22.7B
P/E
0.0×
Fwd P/E
−17.4×
Dividend yield
—
F-score
4/9
Altman Z
n/a
Beneish M
−2.74
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
7.81 7.05 7.09 6.68
P/FCF ratio
47.08 39.95 0.00 0.00
P/Operating CF
1,525.76 (45.68) 66.76 26.47
P/B ratio
1.14 1.03 1.06 1.09
EV/Sales
2.24 1.80 2.00 1.95
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
13.49 10.17 (19.85) (5.60)
Current Ratio
7.85 8.80 7.54 7.12
Net Debt/EBITDA
21.18 25.78 73.50 (178.52)
Debt/Equity
0.02 0.02 0.01 0.01
Earnings Yield
(8.41%) (6.62%) (5.50%) (2.67%)
Free Cash Flow Yield
2.12% 2.50% (1.42%) (5.22%)
Free Cash Flow per Share
(0.18) (2.30) 1.24 3.46
Book value per Share
81.50 86.41 89.99 90.31
Free Cash Flow
(44.42) (583.21) 300.71 827.64
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates